The present disclosure relates to methods of manufacture for producing anti-IL-12/IL-23p40 antibodies, e.g., the anti-IL-12/IL-23p40 antibody ustekinumab, and specific pharmaceutical compositions of the antibody.

The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

In the field of therapy, specifically patient-specific immune therapy for cancer, improved therapeutic modalities are provided for. The identity and dosage of the administered anti-tumor antibodies is determined and dynamically adjusted to the individual patient's condition, disease and/or treatment progression, thus providing anti-cancer treatment which may be particularly advantageous for the treatment of heterogeneous tumors.

A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a B cell from a rabbit having a B4 allotype with a 240E cell or a derivative thereof to produce a hybridoma, wherein the B cell and the hybridoma produce a monoclonal antibody; making cDNA from the hybridoma; amplifying from the cDNA a full length coding sequence for the light chain of a monoclonal antibody produced by the hybridoma using: a forward primer that hybridizes to a site in SEQ ID NO: 10, and a reverse primer having a 3′ end of sequence CTARCAGTCX (SEQ ID NO: 11), wherein R is A or G and X is A, AC, ACC or ACCC; and cloning the amplified sequence into an expression vector to produce a first plasmid.

Method for the treatment of virus infection with IVIG and convalescent plasma. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of intravenous Immunoglobulin G (IVIG) in an amount of about 0.5 g/kg to about 8 g/kg. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of convalescent anti-SARS-CoV-2 plasma, wherein the convalescent anti-SARS-CoV-2 plasma is treated with methylene blue for pathogen inactivation.

Compositions and methods involving effector cells armed with antiviral antibodies are disclosed herein. Such compositions may also include additional antiviral treatments and may be used, for example, to treat subjects having a viral infection (e.g., SARS-CoV-2).

A method for generating a plurality of diverse camelid antibodies to cover functional epitopes of the target with high-resolution. Also provided is a method for generating camelid antibodies.

Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that are internalized via this pathway are provided as well as immunoconjugates comprising such antibodies.

The present disclosure provides materials and methods for cloning antibodies from single cells in pooled sequence libraries by selective PCR. The compositions and methods relate to isolating, cloning, and/or expressing one or more antibody sequences from a single cell from a pool of cells.